 |
A US Food and Drug Administration (FDA) advisory committee has recommended that the agency approve marketing of Fampridine-SR (Acorda Therapeutics, with a proposed name change to Amaya) for its ability to improve walking speed in people with any type of MS.
To read more, as reported by the US National MS Society, click here.
Source: US National MS Society
|
